Vlad Coric, Biohaven CEO

Vlad Coric charts course for new Bio­haven with neu­ro­science push and Big Phar­ma vets on board

What’s Bio­haven with­out its CGRP port­fo­lio? That’s what CEO Vlad Coric is tasked with de­cid­ing as he maps out the new Bio­haven post-Pfiz­er takeover.

Pfiz­er of­fi­cial­ly scooped up Bio­haven’s CGRP as­sets on Mon­day, in­clud­ing block­buster mi­graine drug Nurtec and the in­ves­ti­ga­tion­al za­veg­epant, for $11.6 bil­lion. As a re­sult, Coric spun the broad­er pipeline in­to an in­de­pen­dent com­pa­ny on Tues­day — with the same R&D team be­hind Nurtec but about 1,000 few­er staffers and a re­newed fo­cus on neu­ro­science and rare dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.